At the end of the latest market close, Bristol-Myers Squibb Company (BMY) was valued at $62.31. In that particular session, Stock kicked-off at the price of $62.19 while reaching the peak value of $62.59 and lowest value recorded on the day was $60.97. The stock current value is $61.20.
Recently in News on December 7, 2020, Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission. Analysis showed treatment with Onureg improved overall survival in patients with both measurable residual disease (MRD) positive status and MRD negative status compared to placebo from the time of randomization. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Bristol-Myers Squibb Company had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $68.34 on 01/22/20, with the lowest value was $45.76 for the same time period, recorded on 03/23/20.
Bristol-Myers Squibb Company (BMY) full year performance was 2.09%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Bristol-Myers Squibb Company shares are logging -10.45% during the 52-week period from high price, and 33.74% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $45.76 and $68.34.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 8916906 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Bristol-Myers Squibb Company (BMY) recorded performance in the market was -4.66%, having the revenues showcasing 4.56% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 137.12B, as it employees total of 30000 workers.
Analysts verdict on Bristol-Myers Squibb Company (BMY)
During the last month, 11 analysts gave the Bristol-Myers Squibb Company a BUY rating, 3 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 60.93, with a change in the price was noted +1.88. In a similar fashion, Bristol-Myers Squibb Company posted a movement of +3.17% for the period of last 100 days, recording 10,123,592 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BMY is recording 0.90 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.82.
Bristol-Myers Squibb Company (BMY): Technical Analysis
Raw Stochastic average of Bristol-Myers Squibb Company in the period of last 50 days is set at 46.92%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 4.50%. In the last 20 days, the company’s Stochastic %K was 14.37% and its Stochastic %D was recorded 19.44%.
Let’s take a glance in the erstwhile performances of Bristol-Myers Squibb Company, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -4.66%. Additionally, trading for the stock in the period of the last six months notably improved by 0.44%, alongside a boost of 2.09% for the period of the last 12 months. The shares increased approximately by -1.92% in the 7-day charts and went up by -4.00% in the period of the last 30 days. Common stock shares were driven by 4.56% during last recorded quarter.